Detalhe da pesquisa
1.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
2.
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 402(10407): 1043-1051, 2023 09 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524096
3.
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.
Oncologist
; 29(2): 91-98, 2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048064
4.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
5.
Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
J Urol
; : 101097JU0000000000003928, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38573872
6.
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.
BJU Int
; 133(3): 297-304, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37548533
7.
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 400(10358): 1103-1116, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099926
8.
Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Oncologist
; 28(10): 894-900, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315114
9.
A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy.
Oncologist
; 28(8): 699-705, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36888587
10.
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Oncologist
; 28(3): e167-e170, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576430
11.
Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Oncologist
; 28(1): 59-71, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35881028
12.
Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.
Oncologist
; 28(9): e748-e755, 2023 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36971500
13.
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
Oncologist
; 28(6): 494-500, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36917626
14.
Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.
Oncologist
; 28(12): 1079-1084, 2023 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432304
15.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36573926
16.
Anxiety, Depression, and Coping Strategies during Chemotherapy Treatment: A Comparison of Older and Younger Adults with Advanced Cancer in Brazil.
Cancer Invest
; 41(9): 781-788, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882784
17.
Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study.
Cancer Invest
; 41(1): 70-76, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239609
18.
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
J Genet Couns
; 2023 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37697864
19.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Lancet Oncol
; 23(7): 899-909, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35690072
20.
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Lancet
; 397(10275): 695-703, 2021 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33592176